Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the...

Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it submitted an Orphan Drug Designation Request to the US Food and Drug Administration...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that it has...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that enrollment...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has signed a Sponsored Research Agreement with North Carolina State University ("NC...

Hoth Therapeutics, Inc., (NASDAQ: HOTH) a patient focused biopharmaceutical company, announced today that it has entered into two contracts with STA Pharmaceutical, a subsidiary of WuXi AppTec...

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence cohort 2 of the Phase 1b...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that a Safety Review Committee (SRC) has reviewed the safety data from the first cohort of...

Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the completed safety results in Cohort 1 of its first in human clinical trial of the...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that its new treatment for mast cell...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model. The...

NEW YORK, July 13, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that its HT-003 group of assets has yielded positive...

Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement with Washington University in St. Louis...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will share positive results from a preclinical trial during its shareholder...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today plans to host a virtual information session on its pipeline product, HT-KIT, a new molecular...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will be an exhibitor at the American Society of Clinical Oncology (ASCO) Annual...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today it plans to host a virtual information session on its pipeline product, HT-005 Z-Pods™, a...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its sponsored research agreement with Virginia Commonwealth University (VCU) for a potential...

Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it intends to pursue development of its HT-KIT mRNA Frame Shifting Therapeutic for multiple

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce the start of its...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, announced that its novel anti-cancer therapeutic exhibited highly positive results in humanized...

Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, together with its manufacturing partner, has successfully completed the formulation for HT-001, a...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced that it has engaged Worldwide Clinical Trials ("Worldwide"), a full-service Contract Research...